Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Published:2021-07-30 Issue:9 Volume:20 Page:1153-1165
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Igarashi Ataru¹²,Hirose Emi³,Kobayashi Yasuhiro³,Yonemoto Naohiro³,Lee Bennett³

Affiliation:

1. Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanagawa, Japan

2. Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan

3. Pfizer Japan Inc., Tokyo, Japan

Funder

Pfizer Japan Inc

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2021.1952869

Reference59 articles.

1. Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/pneumococcal/about/index.html Accessed:25 March, 2021.

2. Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

3. Infectious Agents Surveillance Report (IASR). National Institute of Infectious Disease. 39 (7), 107–108(2018) https://www.niid.go.jp/niid/images/idsc/iasr/39/461.pdf Accessed 2021 Jun 10

4. The Burden and Etiology of Community-Onset Pneumonia in the Aging Japanese Population: A Multicenter Prospective Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Structured Narrative Literature Review of the Broader Value of Adult Immunisation Programmes;Vaccines;2024-07-29

2. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan;Expert Review of Vaccines;2024-05-09

3. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan;Expert Review of Vaccines;2024-05-02

4. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan;Vaccines;2024-04-18

5. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection;Preventive Medicine;2024-01